Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

NCT03135951 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Pharmacokinetics

Interventions

DRUG: SPI-2012

Sponsor

Spectrum Pharmaceuticals, Inc